CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 90 filers reported holding CYTOSORBENTS CORP in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,800 | -47.6% | 10,000 | 0.0% | 0.02% | -40.7% |
| Q2 2023 | $35,900 | +6.5% | 10,000 | 0.0% | 0.03% | +3.8% |
| Q1 2023 | $33,700 | +117.4% | 10,000 | 0.0% | 0.03% | +116.7% |
| Q4 2022 | $15,500 | +10.7% | 10,000 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $14,000 | -36.4% | 10,000 | 0.0% | 0.01% | -33.3% |
| Q2 2022 | $22,000 | -31.2% | 10,000 | 0.0% | 0.02% | -14.3% |
| Q1 2022 | $32,000 | -23.8% | 10,000 | 0.0% | 0.02% | -22.2% |
| Q4 2021 | $42,000 | -48.1% | 10,000 | 0.0% | 0.03% | -55.0% |
| Q3 2021 | $81,000 | +6.6% | 10,000 | 0.0% | 0.06% | +7.1% |
| Q2 2021 | $76,000 | -12.6% | 10,000 | 0.0% | 0.06% | -18.8% |
| Q1 2021 | $87,000 | +8.8% | 10,000 | 0.0% | 0.07% | 0.0% |
| Q4 2020 | $80,000 | 0.0% | 10,000 | 0.0% | 0.07% | -4.2% |
| Q3 2020 | $80,000 | -19.2% | 10,000 | 0.0% | 0.07% | -33.9% |
| Q2 2020 | $99,000 | +28.6% | 10,000 | 0.0% | 0.11% | +17.2% |
| Q1 2020 | $77,000 | +102.6% | 10,000 | 0.0% | 0.09% | +126.8% |
| Q4 2019 | $38,000 | – | 10,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 675,000 | $918,000 | 1.02% |
| Sargent Investment Group, LLC | 1,108,233 | $2,028,000 | 0.63% |
| Skylands Capital, LLC | 2,347,034 | $3,192,000 | 0.52% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 253,000 | $344,000 | 0.37% |
| Avenir Corp | 2,314,854 | $3,148,000 | 0.33% |
| Granahan Investment Management | 1,511,029 | $2,055,000 | 0.07% |
| ACT CAPITAL MANAGEMENT, LLC | 35,000 | $48,000 | 0.07% |
| Winning Points Advisors, LLC | 22,900 | $33,000 | 0.04% |
| Cowen Prime Advisors LLC | 42,200 | $57,000 | 0.03% |
| Seelaus Asset Management LLC | 23,900 | $33,000 | 0.03% |